Related references
Note: Only part of the references are listed.Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
LANCET (2010)
Lipoprotein-associated phospholipase A(2) : role in atherosclerosis and utility as a cardiovascular biomarker
Peter P. Toth et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2010)
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
K. G. M. M. Alberti et al.
CIRCULATION (2009)
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2009)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Paul M. Ridker et al.
LANCET (2009)
The epidemiology of Lp-PLA2:: Distribution and correlation with cardiovascular risk factors in a population-based cohort
Margaretha Persson et al.
ATHEROSCLEROSIS (2007)
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients
S Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
SM Grundy et al.
CIRCULATION (2005)
Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6
HS Park et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2005)
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/1 -: An analysis of the PROVE-IT TIMI-22 trial
PM Ridker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Metabolic syndrome - A comprehensive perspective based on interactions between obesity, diabetes, and inflammation
P Dandona et al.
CIRCULATION (2005)
Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome
D Aronson et al.
INTERNATIONAL JOURNAL OF OBESITY (2004)
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
CM Ballantyne et al.
CIRCULATION (2004)
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
PM Ridker et al.
CIRCULATION (2004)
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure - The JNC 7 Report
AV Chobanian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events
PM Ridker et al.
CIRCULATION (2003)
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study
TS Han et al.
DIABETES CARE (2002)
Inflammation and atherosclerosis
P Libby et al.
CIRCULATION (2002)
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.
CJ Packard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
